Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Gloria Iacoboni, MD, Josu Iraola-Truchuelo, Nuria Martinez-Cibrian, MD, Rebeca Bailén, MD, Lucia Lopez Corral, PhD MD, Jose M. Sanchez, MD, Manuel Guerreiro, MD, ANA Carolina Carolina CABALLERO González, Alberto Mussetti, MD, Juan-Manuel Sancho, MD PhD, Rafael Hernani, MD, Carlos Solano, MD PhD, Anna Sureda Balari, MD PhD, Javier Briones, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Mi Kwon, MD PhD, Juan Luis Reguera, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136201

Published: 2020

Journal Articles

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Gloria Iacoboni, MD, Marc Simo, MD, Guillermo Villacampa, Eva Catala, Cecilia Carpio, MD, Candido Diaz-Lagares, MD, Angela Vidal-Jordana, MD, Sabela Bobillo, MD, Ana Marin-Niebla, MD PhD, Ana Perez, MD, Moraima Jiménez, Pau Abrisqueta, MD PhD, David Valcárcel, MD PhD, Francesc Bosch, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-141777

Published: 2020

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Carmelo Carlo-Stella, MD, Emmanuel Bachy, MD PhD, Fritz C. Offner, MD PhD, Franck Morschhauser, MD PhD, Michael Crump, Gloria Iacoboni, MD, Anna Sureda Balari, MD PhD, Joaquin Martinez-Lopez, MD, Linda Lundberg, Mark Dixon, David Perez Callejo, James Relf, David Carlile, Emily Piccione, Kathryn Humphrey, Michael Dickinson, DMed Sci

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-136044

Published: 2020

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

Juan C Nieto, PhD, Elisa Roldan, MD, Isabel Jiménez, MSc, Laura Fox, Júlia Carabia, PhD, Guillermo Orti, Lluis Puigdefàbregas, Laura Gallur, Gloria Iacoboni, MD, Priyanka Raheja, Ana Perez, Olga Salamero, MD, Carlos Palacio, David Valcarcel, MD, Marta Crespo, PhD, Francesc Bosch, MD, Pere Barba, MD

Blood (2018) 132 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2018-99-114887

Published: 2018

Journal Articles

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Franck Morschhauser, MD, Fritz Offner, MD, Anna Sureda, MD, Gilles Andre Salles, MD PhD, Carmelo Carlo-Stella, MD, Joaquin Martinez Lopez, MD, Denise Thomas, BS, Peter N Morcos, PhD, Betsy Quackenbush, MD, Cristiano Ferlini, MD, Marina Bacac, PhD, Ann-Marie E. Broeske, PhD, Natalie Dimier, PhD, Tom Moore, MD, Martin Weisser, MD, Michael Dickinson, MD

Blood (2018) 132 (Supplement 1): 226.

https://doi.org/10.1182/blood-2018-99-110207

Published: 2018

NARROW

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Email alerts

ASH Publications

American Society of Hematology

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only